Measuring Small-Airways Disease Improvement After Step-up to Extrafine TRIple or High-dose ICS/LABA in Patients Uncontrolled on Medium Dose ICS/LABA eXploring T2 Inflammation

Inclusion Criteria: * Males and females out-patients aged ≥18 years providing written informed consent. \[Note: Females are eligible if they are of non-childbearing potential or, if they are of childbearing potential, using or are willing to use appropriate contraceptive measures.\] * Physician-diagnosed asthma for at least 6 months * Patients with uncontrolled asthma (ACT\<20 or ACQ-5\>1.5) on stable treatment with medium dose ICS/LABA for at least 12 weeks and with good adherence to treatment. * Evidence of SAD as expressed by FEF25-75% \<60% in spirometry. * Ability to be trained to use properly a pMDI inhaler (with or without spacer as per physician's judgement). * Documented decision in the patient's medical file for the (high-dose ICS regimen or medium dose efSITT) before the patient gets informed about his/her potential participation in the study. Exclusion Criteria: * Age \<18 years * Patients who have experienced a severe asthma exacerbation (i.e. receiving OCS for at least 3 days and/or antibiotics or need for hospitalisation) in the 4 weeks prior to the screening visit. * Refusal or inability to give informed consent. * Patients with COPD or other respiratory disease, e.g. bronchiectasis, cystic fibrosis, interstitial lung diseases or any other clinically or functionally significant lung disorder, cancer (except localized carcinomas), or other clinically significant comorbidities that may affect the outcomes measured. * Long-term oxygen therapy at home. * Pregna…